Review Article
The Role of Transoral Robotic Surgery in the Management of Oropharyngeal Cancer: A Review of the Literature
Table 5
Functional outcomes following TORS for OPSCC.
| Study | Number of cases | Primary site | Pathological stage | HPV status | Followup period (mean) | Hospital stay (mean) | Tracheostomy dependent (days to decannulation) | Gastrostomy tube dependency |
| Weinstein et al. [11] | 27 | Oropharynx | T1/2: 21 | N/A | N/A | N/A | 0% | 4% (1/27) | (Dec ’07) | | | T3/4: 6 | | | | | | | | | | | | | | | | | | N0: 4 | | | | | | | | | N1: 13 | | | | | | | | | N2a: | | | | | | | | | N2b: −10 | | | | | | | | | N2c: | | | | | | | | | N3: 0 | | | | | |
| Genden et al. [16] (Mar ’09) | 20 (18 completed cases) | 14 oropharynx | T1/2: 20/20 | N/A | N/A | 1.7 d | 0% | 0% | | | 4 supraglottis | | | | | | | | | 2 parapharyngeal | N0: 11 | | | | | | | | | N1: 6 | | | | | | | | | N2: 3 | | | | | | | | | N3: 0 | | | | | |
| Boudreaux et al. [18] (Apr ’09) | 36 (29 completed cases) | 19 oropharynx (66%) | T1/2: 29 | N/A | N/A | 2.9 d | 0% | Overall: 31% | | | 7 larynx (24%) | T3/4: 7 | | | | | oropharynx 3/19 (16%) | | | 2 oral cavity (7%) | | | | | | larynx 6/7 (86%) | | | 1 hypopharynx (3%) | Stage 1: 6 (17%) | | | | | oral cavity 0/2 (0%) | | | | Stage 2: 8 (22%) | | | | | hypopharynx 0/1 (0%) | | | | Stage 3: 3 (8%) | | | | | | | | | Stage 4: 19 (53%) | | | | |
%) |
| Iseli et al. [33] (May ’09) | 54 | 33 oropharynx | T1/2: 43 | N/A | 13 mths | N/A | 0% | Overall (no previous treatment): 9% | | | 12 larynx | T3/4: 11 | | | | | oropharynx 2/33 (6%) | | | 6 oral cavity | | | | | | larynx 5/12 (42%) | | | 3 hypopharynx | N-stage: N/A | | | | | oral cavity 1/6 (17%) | | | | | | | | | hypopharynx 1/3 (33%) |
| Moore et al. [14] | 45 | Oropharynx | T1/2: 33 | N/A | 12.3 mths | 3.8 d | 0% | 0% | (Nov ‘09) | | | T3/4: 12 | | | | (2–180) | | | | | | | | | | | | | | N0: 7 | | | | | | | | | N1: 7 | | | | | | | | | N2a: 7 | | | | | | | | | N2b: 13 | | | | | | | | | N2c: 8 | | | | | | | | | N3: 3 | | | | | |
| Dean et al. [26] (Apr ’10) | 36 | Oropharynx | T1/2: 36/36 | N/A | N/A | 1.5 d (TORS primary) | 0% primary TORS | 0% primary TORS | | 15 primary TORS | | | | |
5 d (TORS salvage group) |
0% salvage TORS |
0% salvage TORS | | 7 salvage TORS | | | | |
8.2 d (open surgery group) |
7% salvage open surgery |
43% salvage open surgery | | 14 salvage open surgery) | | | | | | |
%) |
| Lawson et al. [19] | 24 | 10 supraglottic | T1/2: 21 | N/A | 17 mths | 9 d | 0% | N/A | (Mar ‘11) | | 10 pharyngeal | T3/4: 1 | | | | | | | | 4 oral cavity | | | | | | | | | | N0: 13 | | | | | | | | | N1: 5 | | | | | | | | | N2a: 2 | | | | | | | | | N2b: 2 | | | | | | | | | N2c: 1 | | | | | | | | | N3: 1 | | | | | |
| Aubry et al. [15] (Sept ’11) | 17 (18 tumors) | 9 oropharynx | T1/2: 15 | N/A | 6.5 mths | 10 d | 0% | 12% (2/17) | | | 7 supraglottis | T3: 3 | | | | | | | | 2 hypopharynx | | | | | | | | | | N0: 12 | | | | | | | | | N1: 4 | | | | | | | | | N2a: 0 | | | | | | | | | N2b: 2 | | | | | | | | | N2c: 0 | | | | | | | | | N3: 0 | | | | | |
|
|